Preclinical studies demonstrated that sotrastaurin (AEB071) and enzastaurin, two adenosine triphosphate-competitive selective inhibitors of PKCβ, induce apoptosis and inhibit the proliferation of BCR-subtypes of ABC-DLBCL in vitro and in vivo [252, 253]. This evidence concerns the gene PRKCB and diffuse large B-cell lymphoma.